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Abstract
The central melanocortin system plays a key role in the
regulation of food intake and energy homeostasis. We
investigated whether genetic or pharmacologic blockade of
central melanocortin signaling attenuates cardiac cachexia
in mice and rats with heart failure. Permanent ligation
of the left coronary artery (myocardial infarction (MI)) or
sham operation was performed in wild-type (WT) or
melanocortin-4 receptor (MC4R) knockout mice. Eight
weeks after surgery, WT-Sham mice had signiﬁcant increases
in lean body mass (LBM; P!0.05) and fat mass (P!0.05),
whereas WT-MI did not gain signiﬁcant amounts of LBM or
fat mass. Resting basal metabolic rate (BMR) was signiﬁcantly
lower in WT-Sham mice compared to WT-MI mice
(P!0.001). In contrast, both MC4-Sham and MC4-MI
mice gained signiﬁcant amounts of LBM (P!0.05) and fat
mass (P!0.05) over the study period. There was no
signiﬁcant difference in the BMR between MC4-Sham and
MC4-MI mice. In the secondexperiment, rats received aortic
bands or sham operations, and after recovery received i.c.v.
injections of either artiﬁcial cerebrospinal ﬂuid (aCSF) or
the melanocortin antagonist agouti-related protein (AGRP)
for 2 weeks. Banded rats receiving AGRP gained signiﬁcant
amount of LBM (P!0.05) and fat mass (P!0.05) over the
treatment period, whereas banded rats receiving aCSF
did not gain signiﬁcant amounts of LBM or fat mass.
These results demonstrated that genetic and pharmacologic
blockade of melanocortin signaling attenuated the metabolic
manifestations of cardiac cachexia in murine and rat models of
heart failure.
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Introduction
Chronic heart failure (CHF) is a major public health problem
in western countries, with an incidence approaching 10 per
1000 population per year in those aged 65 years or older
(Cowie et al. 1999, Lloyd-Jones et al. 2002). In the United
States,CHFcontributedtow284 365deathsin2004,andthe
estimated direct and indirect health care costs to patients
withCHFfor2008were$34.8billion(Rosamondetal.2008).
TheprognosisofCHFpatientsissigniﬁcantlyworsenedbythe
development of cachexia, a wasting condition that also
manifests itself in other chronic illnesses, including cancer,
chronic renal failure, AIDS, and inﬂammatory bowel disease
(Tisdale 1997). Cardiac cachexia is a complex metabolic
disorder involving features of anorexia, catabolism of protein
and fat, reductions in bone mineral density, activation of acute
phase response, and insulin resistance (Tisdale 1997). CHF
patients that develop cardiac cachexia have increased
morbidity and mortality compared to CHF patients who do
not become cachectic, an effect that is independent of left
ventricular function (Anker et al. 1997). Indeed, one study
demonstrated that the mortalityat 18 months in CHF patients
that had been diagnosed with cardiac cachexia was as high as
50% compared with 17% in patients with CHF that did not
develop cardiac cachexia (Anker et al. 1997).
Although the exact molecular mechanisms that initiate
and maintain the cachectic state in CHF remain largely
unresolved, there is increasing evidence to suggest that
increased production of proinﬂammatory factors including
cytokines, chemokines, and eicosanoids may play a crucial
role in the pathogenesis of cardiac cachexia. Speciﬁcally,
there has been an increased focus placed on the potential role
of proinﬂammatory cytokines in the pathogenesis of
cardiac cachexia, as elevated serum levels of tumor necrosis
factor-a (TNF-a), interleukin-1b (IL-1b), and IL-6 have
been measured in CHF patients with cardiac cachexia
(Levine et al. 1990, Dutka et al. 1993, Anker et al. 1999).
Administration of proinﬂammatory cytokines, either
peripherally or centrally, induces anorexia, weight loss, and
activation of the hypothalamic–pituitary–adrenal axis
(Plata-Salaman et al. 1996, Plata-Salaman 2001). The meta-
bolic and behavioral responses elicited by proinﬂammatory
cytokines are hypothesized to occur via their interaction
with circuits in the central nervous system that regulate
metabolism and food intake (Campbell 1998, Reyes &
Sawchenko 2002).
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is the central melanocortin system. The central melanocortin
system plays a critical role in the regulation of feeding
behavior, linear growth, and metabolic rate (Baskin et al.
1999, Cone et al. 2001). This occurs principally via the action
of a-melanocyte-stimulating hormone (a-MSH), a peptide
derived from the proopiomelanocortin (POMC)-expressing
neuronsinthehypothalamusandbrainstem(Cone2005).The
feeding and metabolic effects of a-MSH are mediated by the
melanocortin-4 receptor (MC4R), a G protein-coupled
receptor expressed predominately in the brain (Cone 2005).
Acute and chronic stimulation of MC4R produces anorexia,
weight loss, and increased metabolic rate (Fan et al. 1997,
Foster et al. 2003), whereas genetic deletion or antagonism of
MC4R by agouti-related protein (AGRP), an endogenous
melanocortin receptor inverse agonist, promotes food intake
and weight gain (Ollmann et al. 1997, Joppa et al. 2005).
Recent studies have shown that the secretion of a-MSH is
increased and the secretion of AGRP is decreased from
hypothalamicexplantsinresponsetoIL1b(Scarlettetal.2007,
2008), demonstrating that central melanocortin signaling can
be increased in response to an inﬂammatory cytokine.
Data from a numberof studies support a critical role for the
central melanocortinsystemin thepathogenesis ofcachexia of
chronic disease. Mice with impaired central melanocortin
signaling due to targeted deletion of the MC4R (MC4RKO)
are resistant to the development of cachexia in models of
lipopolysaccharide (LPS) sepsis (Marks et al. 2001), cancer
(Marksetal.2001),andacuterenalfailure(Cheungetal.2005).
Pharmacologic blockade of MC4R signaling with AGRP has
beenshowntoattenuatecachexiainamurinemodelofcancer
cachexia (Joppa et al. 2007). Ghrelin, a gut-derived peptide
agonist for the GH secretagogue receptor that also potently
inhibits central melanocortin signaling by increasing Agrp
mRNA expression (Kamegai et al. 2000) and hyperpolarizing
POMC neurons (Cowley et al. 2003), has been shown to
attenuate the development of cachexia in rat models of CHF
(Nagaya et al. 2001). Collectively, these data support a direct
role for the central melanocortin system in the pathogenesis
of cardiac cachexia and suggest that blockade of central
melanocortin signaling may represent a potential therapy for
cardiac cachexia. There is an important drawback to these
studies in that the duration of the inﬂammatory insult was
either acute (e.g. LPS injection) or subacute (e.g. cancer
models), and it remains unclear whether melanocortin
blockade is a realistic therapeutic target for diseases with a
more indolent course (e.g. congestive heart failure, COPD).
In the present paper, we show that chronic blockade of
central melanocortin signaling using genetic and pharmaco-
logic techniques is able to attenuate the metabolic mani-
festations of cardiac cachexia in murine and rat models of heart
failure. To our knowledge, these studies are the ﬁrst to reveal a
keyroleforthecentralmelanocortinsysteminthepathogenesis
of cardiac cachexia, and demonstrate the effectiveness of
prolonged antagonismofmelanocortinsignaling inattenuating
cachexia in an animal model of chronic illness.
Materials and Methods
Animals
Male wild-type (WT) C57BL/6J mice (6–8 months of age;
Jackson Laboratory), MC4RKO mice (6–8 months of age;
raised in C57BL/6J background), and male Wistar rats
(40–50 g; Charles River Laboratories, Wilmington, MA,
USA) were maintained on a normal 12 h light:12 h darkness
cycle with ad libitum access to food (Purina rodent diet 5001;
Purina Mills) and water. Experiments were conducted in
accordance with the NIH Guide for the Care and Use of
Laboratory Animals, and approved by the Animal Care and
Use Committees of Oregon Health and Science University.
Murine myocardial infarction surgeries
Prior to the surgeries, mice were divided into four groups:
WT sham-operated (WT-Sham, nZ22), WT myocardial
infarcted (WT-MI, nZ23), MC4RKO sham-operated
(MC4-Sham, nZ19), and MC4RKO MI (MC4-MI,
nZ18). Overall surgical mortality was 14% for WT-Sham
group, 35% for WT-MI group, 11% for MC4-Sham group,
and 39% for MC4-MI group. Permanent myocardial infarcts
were produced in WTand MC4RKO mice by ligation of the
anterior descending branch of the left coronary artery as
previously described (Gould et al. 2002). Brieﬂy, mice were
anesthetized with i.p. pentobarbital sodium (4 mg/ml,
14 ml/g body weight (BW), Nembutal, Abbott Laboratories),
placed in a supine position, and intubated. Mice were
ventilated with a mixture of 100% oxygen and room air with
a mechanical rodent Mini-Vent ventilator (100 cycles/min,
Harvard Apparatus, Holliston, MA, USA). Ventilator stroke
volume was adjusted to fully inﬂate but not overexpand the
lungs. A lateral sternotomy was performed, exposing the
anterior surface of the heart. The anterior descending branch
of the left main coronary artery (LAD) was ligated at a
position w1 mm from the tip of the normally positioned left
auricle with a 7–0 polypropylene monoﬁlament suture
(Prolene, Ethicon, Somerville, NJ, USA). The ligature was
not removed after placement. Sham operations were created
by passing the suture under the coronaryartery at the position
used for ligation without ever constricting the artery. After
chest closure, mice were recovered in a sternal position,
warmed, and provided with 100% oxygen by nose cone.
Post-operative analgesia was extended with a single s.c.
injection of 2.5 mg/kg buprenorphine (Buprenex, Reckitt
and Colman Pharmaceuticals; Richmond, VA, USA). Mice
must have survived 8 weeks after surgery to be included in the
body composition and indirect calorimetry studies.
Murine body composition
Body composition was determined before infarction surgeries
and the end of the experiment by dual-energy X-ray
absorptiometry (DEXA, PIXImus mouse densitometer,
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calibrated at the start of each recording session with a murine
calibration standard. All animals were fasted for 12 h before
DEXA analysis to minimize the effect of ingested food on the
DEXA analysis. Individual organ weights (including heart,
liver, lung, and spleen) were measured at necropsy at the end
of the ﬁnal DEXA scan.
Murine indirect calorimetry
Oxygen consumption (VO2) was determined by indirect
calorimetry (Oxymax, Columbus Instruments, Columbus,
OH, USA). Mice were housed in separate chambers at
24G1 8C. Mice were ﬁrst acclimatized to the chambers for
2 days prior to conducting the study. Measurements were
recorded for 4–8 h during the middle of the light cycle
(1100–1600 h). Samples were recorded every 3 min with the
room air reference taken every 30 min and the air ﬂow to
chambers 500 ml/min. Basal oxygen consumption was
determined for individual curves as the average of the lowest
plateau regions corresponding to resting periods. Total
oxygen consumption was the result of all samples recorded
corresponding to periods of movement as well as inactivity.
Rat aortic banding surgeries
Male Wistar rats (nZ40) were anesthetized by i.p. injection of
pentobarbital sodium (60 mg/kg BW). Rats were ventilated
with a mixture of 100% oxygen and room air by mechanical
ventilation at a tidal volume of 320 ml and a frequency of
120 bpm (MiniVent, Harvard Apparatus). Aortic stenosis
(nZ22) was induced via a left thoracic incision by banding
the ascending aorta with titanium clips (Weck Atrauclip,
0.6 mm internal diameter) as previously described (Helies-
Toussaint et al. 2005). The Sham group consisted of sham-
operated rats (nZ18) prepared by a similar surgical treatment
without placement of the clip. After chest closure, rats were
recovered in a sternal position, warmed, and provided with
100% oxygen by nose cone. Post-operative analgesia was
extended with a single s.c. injection of 2.5 mg/kg buprenor-
phine. Surgical mortality was 18% for banded rats and 11% for
sham-operated rats. The rats were group housed until the
sham-operated rats reached an average weight of 200 g, at
which time both sham-operated and banded rats were
separated into individual cages for food intake and BW
measurement studies.
Rat i.c.v. cannulation and injections
Cannulation implantation was performed when the average
weight of the sham-operated rats reached 300 g. Sham- and
aortic-banded rats were anesthetized as described above and
placed in a stereotaxic apparatus (Cartesian Research, Inc.,
Sandy, OR, USA). A sterile guide cannula with obturator
styletwasimplanted1 mmlateraltobregma,1.5 mmposterior
to bregma, and 3.6 mm below the surface of the skull.
The cannulawas then ﬁxed in place with dental cement. After
surgery,theratsweredividedintofourgroups:sham-operated,
artiﬁcial cerebrospinal ﬂuid (aCSF)-treated (Sham-aCSF,
nZ8); sham-operated, AGRP treated (Sham-AGRP, nZ8);
banded, aCSF-treated (Band-aCSF, nZ9); and banded,
AGRP-treated (Band-AGRP, nZ9), and remained individu-
allyhousedandallowed5daystorecoverbeforereceivingtheir
ﬁrst DEXA scan and beginning the treatment period. During
recovery, the rats were handled daily and administered 5 ml
i.c.v. injections of commercial aCSF (Harvard Apparatus)
daily. During the 2-week treatment period, animals received
5 ml injections of either aCSF or 1 nmol AGRP (Phoenix
Pharmaceuticals, Burlingame, CA, USA) dissolved in 5 ml
aCSFonceevery48 hforatotalofeightinjections.OneBand-
AGRP, two Band-aCSF, and two Sham-aCSF rats lost their
cannulas prior to the completion of the 2-week treatment
period, and were excluded from the ﬁnal analysis.
Rat body composition
Body composition was determined before and after the
2-week AGRPor aCSF treatment period by DEXA (Hologic
QDR Discovery A Densitometer) at the OHSU General
Clinical Research Center Body Composition core. All
animals were fasted for 12 h before DEXA analysis to
minimize the effect of ingested food on the DEXA analysis.
Individual organ weights were measured at necropsy at the
end of the ﬁnal DEXA scan. Feed efﬁciency was calculated by
dividing the total weight gained by the total amount of food
consumed over the 14-day treatment period. The ratio of lean
body mass (LBM) to total body water was determined using
quantitative magnetic resonance (EchoMRI, Houston, TX,
USA) by the Cincinnati Mouse Metabolic Phenotyping
Center as previously described (Tinsley et al. 2004).
Organ necropsy
A macroscopic necropsy was done for each animal at the time
of killing. The heart was removed, the atria and great vessels
were removed, and the combined weight of the ventricles and
septum was weighed. The liver and kidneys were also
removed and weighed. Rat brains were removed, and
hypothalamic blocks were dissected out and stored in
RNAlater (Ambion, Inc., Austin, TX, USA) at K80 8C.
RNA preparation and reverse transcription-PCR
Total RNA was extracted from mice and rat hypothalamic
blocks and rat calf muscle using Qiagen RNeasy kits (Qiagen,
Inc). DNA was removed from total RNA using RNase-free
DNase (Qiagen Inc). Reverse transcription (RT) reactions
were prepared using a TaqMan RT Kit (Applied Biosystems,
Inc., Foster City, CA, USA).
Real-time RT-PCR was performed on an ABI 7300
Real-Time PCR System using rat-speciﬁc primer probe sets
obtained from Applied Biosystems. Samples and endogenous
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assure repeatability. Auto Ct valueswere calculated using 7300
RQ Study Software v.1.3 and veriﬁed.
Serum TNF-a measurement
Blood samples were collected in disodium EDTA vacutainers
with added aprotinin (500 KIU/ml of blood) and centrifuged
at 1600 g for 15 min at 4 8C. Serum samples were stored at
K80 8C until assayed for TNF-a. Serum TNF-a concen-
trations were determined using species-speciﬁc, commercially
available ELISA kits (R&D Systems, Minneapolis, MN, USA)
following the manufacturer’s protocol. Radioactive counts
were measured using an automated gamma-counter
(Beckman LS6500). All samples were run in duplicate.
Statistical analysis
Data are expressed as meanGS.E.M. for each group. Statistical
analysis was performed using SPSS (v. 14.0; Chicago, IL,
USA) and Prism (v. 5.0) software. Comparisons of data
between the four groups were made with one-way ANOVA,
followed by a post-hoc analysis using a Bonferroni multiple
comparison test. Changes during treatment were analyzed
with a two-way ANOVA for repeated measures followed by a
Bonferroni test. Comparisons between two groups were
made by unpaired Student’s t-test. Survival was calculated by
Kaplan–Meier life table estimates. Group survivals were
compared by a log-rank test for homogeneity. For all analyses,
signiﬁcance was assigned at the P!0.05 level.
Results
WT mice develop cardiac cachexia following MI
Eight weeksafter surgery, the heart weights (HWs) of WT-MI
mice (nZ15) were signiﬁcantly increased compared to
WT-Sham mice (nZ19) (WT-MI 0.32G0.01 g versus
WT-Sham 0.16G0.01 g, P!0.001; Table 1). The HW-to-
BW ratio (HW:BW), a well-established index of cardiac
hypertrophy, was signiﬁcantly greater for WT-MI mice
compared to WT-Sham mice (WT-MI 13.7G0.54 g versus
WT-Sham 6.39G0.17 g, P!0.001; Table 1). The wet lung
weights of WT-MI mice were signiﬁcantly greater than
WT-Sham mice (WT-MI 0.29G0.06 g versus WT-Sham
0.21G0.01 g, P!0.001; Table 1). Serum concentration of
TNF-a was not signiﬁcantly different between WT-MI
and WT-Sham mice (WT-MI 0.18G0.04 pg/ml versus
WT-Sham0.11G0.05 pg/ml,PZNS).WT-MImiceexperi-
enced signiﬁcantly greater mortality compared to WT-Sham
mice (P!0.001, Fig. 1). Of 34 WT-MI mice, 14 (41%)
Table 1 Characterization of wild-type versus MC4RKO mice. Data are expressed as meanGS.E.M.
WT-Sham WT-MI MC4-Sham MC4-MI
Number 19 15 17 11
Body weight (g)
Baseline 30.82G0.78 30.44G0.92 43.02G1.20* 42.75G1.55*
After treatment 39.93G1.37
‡ 29.77G1.02 51.68G1.09*
,‡ 52.26G1.24*
,‡
Food intake (g/day)
Baseline 4.54G0.08 4.37G0.11 6.75G0.15* 6.78G0.17*
Percentage of body weight 14.81G0.29 14.47G0.52 15.91G0.67 15.99G0.65
8 weeks 4.67G0.07 3.91G0.09
†,‡ 6.73G0.10* 6.64G0.12*
Percentage of body weight 11.98G0.48
‡ 12.84G0.28
‡ 13.09G0.34
‡ 12.77G0.40
‡
Heart (g) 0.16G0.01 0.32G0.01
† 0.18G0.01 0.32G0.01
†
HW:BW ratio (mg/g) 4.13G0.19 10.9G0.57
† 3.53G0.11 6.20G0.19*
HW:LBM ratio (mg/g) 6.39G0.17 13.7G0.54
† 5.90G0.21 10.4G0.35*
Lung (g) 0.21G0.01 0.29G0.06
† 0.20G0.01 0.32G0.02*
Lung:BW ratio (mg/g) 5.50G0.29 10.05G0.61
† 4.14G0.18 6.05G0.42*
Kidney (g) 0.24G0.01 0.20G0.01
† 0.25G0.01* 0.23G0.01*
Kidney:BW ratio (mg/g) 6.10G0.28 6.75G0.23 4.81G0.16* 4.49G0.25*
Liver (g) 1.39G0.06 1.08G0.03 3.38G0.20* 2.92G0.19*
Liver (% of body weight) 3.51G0.14 3.63G0.12 6.51G0.34* 5.58G0.31*
,†
Lean body mass (g)
Baseline 22.58G0.26 22.96G0.39 27.06G0.46* 26.95G0.78*
Percentage of body weight 73.34G1.44 76.28G1.84 63.29G1.16* 63.55G2.18*
After treatment 25.14G0.45
‡ 22.83G0.41
† 30.95G0.52*
,‡ 30.70G0.57*
,‡
Percentage of body weight 63.82G1.63
‡ 77.54G1.98
† 59.61G0.78
‡ 58.88G1.17*
Fat mass (g)
Baseline 8.27G0.58 7.35G0.56 16.30G0.82* 16.37G1.08*
Percentage of body weight 26.72G1.21 23.82G1.71 37.71G1.11* 38.11G1.85*
After treatment 14.56G0.99
‡ 8.11G0.98
† 20.76G0.68*
,‡ 21.81G0.99*
,‡
Percentage of body weight 35.16G1.59
‡ 27.07G3.22
† 40.01G0.61 41.55G1.11*
WT, wild-type mice; MC4, MC4RKO mice; Sham, sham-operated mice; MI, myocardial infarction. *P!0.05 versus respective WT group;
†P!0.05 versus
respective Sham group;
‡P!0.05 versus baseline.
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WT-Sham mice. Prior to surgery, WT-Sham and WT-MI
micehadequalbaselinedailyfoodintake(Table1),but8weeks
after surgery, the daily food intake of WT-Sham mice was
signiﬁcantly greater than WT-MI mice (WT-Sham 4.67
G0.07 g versus WT-MI 3.91G0.09 g, P!0.01; Table 1).
Daily food intake for WT-Sham mice did not signiﬁcantly
change over the course of the study (Table 1), butsigniﬁcantly
declined for WT-MI mice (Table 1). WT-Sham mice gained a
signiﬁcant amount of weight in the period after surgery
(Table 1), but WT-MI mice failed to gain weight over the
courseofthestudy(Table1).SigniﬁcantaccumulationofLBM
and fat massafter surgeryoccurredin WT-Sham mice, butnot
in WT-MI mice (Table 1). The percent increase in LBM per
animalover the courseofthestudy wassigniﬁcantlyhigherfor
WT-Sham mice compared with WT-MI mice (WT-Sham
11.24G1.11% versus WT-MI 1.73G1.27%, P!0.001;
Fig. 2). Kidney and liver weights were higher in WT-Sham
mice compared to WT-MI mice (Table 1) with the difference
in kidney weights being signiﬁcant (WT-Sham 0.24G0.01 g
versus WT-MI 0.20G0.01 g, P!0.01; Table 1). Eight weeks
aftersurgery,therestingmetabolicratewassigniﬁcantlyhigher
in WT-MI mice (2826G78 ml/kg per h) compared to
WT-Sham mice (2371G59 ml/kg per h; P!0.001; Fig. 3).
MC4RKO mice resist cardiac cachexia following MI
To test the role of the MC4R in the pathogenesis of cardiac
cachexia, we performed sham (MC4-Sham) and MI
(MC4-MI) surgeries in MC4RKO mice. Eight weeks after
surgery, the HWs of MC4-MI mice (nZ11) were signi-
ﬁcantly increased compared with MC4-Sham mice (nZ17)
(MC4-MI 0.32G0.01 g versus MC4-Sham 0.18G0.01 g,
P!0.001; Table 1), and these values were not different
compared to their respective WT-Sham and WT-MI groups
(PZNS; Table 1). The HW:BW ratio was signiﬁcantly
greater for MC4-MI mice compared with MC4-Sham mice
(MC4-MI 6.20G0.19 g versus MC4-Sham 3.53G0.11 g,
P!0.001; Table 1). Wet lung weights of MC4-MI mice were
signiﬁcantly increased compared with MC4-Sham mice
(MC4-MI 0.32G0.02 g versus MC4-Sham 0.20G0.01 g,
P!0.001; Table 1), and these values were not different
compared to their respective WT-Sham and WT-MI groups
(PZNS; Table 1). Serum concentrations of TNF-a were not
signiﬁcantly different between MC4-MI and MC4-Sham
mice (MC4-MI 0.19G0.09 pg/ml versus MC4-Sham
0.10G0.07 pg/ml, PZNS), and were not signiﬁcantly
different compared to WT-MI and WT-Sham mice.
MC4-MI mice experienced signiﬁcantly greater mortality
compared with MC4-Sham mice (P!0.001, Fig. 1). Of 19
MC4-MI mice, 11 (58%) survived to the end of the study,
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Figure 2 MC4RKO mice resist cardiac cachexia and increase LBM
accumulation after myocardial infarction. Data are meanGS.E.M.
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Figure 3 MC4RKO resist an increase in energy expenditure in
response to CHF. Basal oxygen consumption during the light phase
(0900–1700 h) is increased in WT-MI mice (nZ15) compared with
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percentage of MC4-MI mice survived to 8 weeks after
surgery compared with WT-MI mice (58 vs 41%), but this
difference failed to reach statistical signiﬁcance in this study.
Prior to surgery, MC4-Sham and MC4-MI mice had equal
baseline daily food intake (Table 1), and the daily food intake
for bothgroups did not signiﬁcantly change over the course of
the study (Table 1). Both MC4-Sham mice and MC4-MI
mice gained signiﬁcant and comparable amounts of BW,
LBM, and fat mass over the course of the study (Table 1).
There was no difference in the percent increase in LBM
(Fig. 2) and fat mass (Table 1) per animal over the course of
the study for MC4-Sham mice compared with MC4-MI
mice, and both groups were signiﬁcantly higher compared to
WT-Sham mice (Fig. 2). At necropsy, the kidney weights and
liver weights were comparable between MC4-Sham and
MC4-MI mice (Table 1). There was no difference in the
resting metabolic rate of MC4-MI mice (1952G146.7 ml/kg
per h) compared with MC4-Sham mice (1918G108 ml/kg
per h; PZNS; Fig. 2).
AGRP administration reverses cardiac cachexia in rats with
pressure overload cardiac hypertrophy
We next examined the effect of i.c.v. AGRP administration
for 2 weeks to reverse cardiac cachexia in a rat model of CHF
induced by aortic banding. Prior to being divided into aCSF
and AGRP treatment groups, rats receiving sham operations
(nZ14) were signiﬁcantly larger than their banded (nZ15)
littermates (Sham 294.5C3.27 g versus Band 266.6C5.03 g;
P!0.001), and had higher daily food intake (Sham 25.50
C0.52 g versus Band 19.67C0.82 g; P!0.001). Sham-
aCSF, Sham-AGRP, and Band-AGRP rats gained signiﬁcant
amounts of BWover the 2-week treatment period, but Band-
aCSF rats failed to signiﬁcantly gain weight (Table 2). Weight
gain, LBM, fat mass accumulation, and kidney weights and
liver weights were signiﬁcantly increased by AGRP treatment
in banded rats (Band-aCSF versus Band-AGRP; Table 2).
The percent increase in LBM per animal over the course of
the study was higher in Sham-aCSF rats compared to Band-
aCSF rats (Sham-aCSF 11.62G2.04% versus Band-aCSF
3.39G2.50%, P!0.05; Fig. 4). AGRP treatment signi-
ﬁcantly increased LBM per animal in banded rats when
expressed both as a percent of baseline (Band-aCSF 3.39
G2.50% versus Band-AGRP 17.90G2.29%, P!0.001;
Fig. 4) and when expressed as absolute grams of tissue (Band-
aCSF 7.12G5.57 g versus Band-AGRP 52.34G5.96 g;
P!0.0001). Feed efﬁciency was signiﬁcantly decreased in
banded rats (Sham-aCSF versus Band-aCSF; Table 2), and
signiﬁcantly increased by AGRP (Band-aCSF versus Band-
AGRP; Table 2). The heart and wet lung weights of banded
ratsweresigniﬁcantlyincreasedcomparedwithsham-operated
Table 2 Characterization of sham versus banded rats. Data are expressed as meanGS.E.M.
Sham-aCSF Sham-AGRP Band-aCSF Band-AGRP
Number 6 8 7 8
Body weight (g)
Baseline 295.0G5.9 294.1G3.8 264.5G8.7* 268.8G5.8*
After treatment 331.3G5.1
‡ 367.5G12.0
‡ 272.8G10.2* 343.3G5.9
†,‡
Food intake (g)
Baseline 26.12G0.53 24.87G0.86 18.85G1.32* 20.61G0.89*
During treatment 26.73G0.99 33.25G2.61
†,‡ 22.26G0.69 34.64G1.66
†,‡
Feed efﬁciency 0.12G0.02 0.16G0.03 0.02G0.03* 0.15G0.01
†
Heart weight (g) 0.84G0.02 0.87G0.03 1.43G0.02* 1.46G0.08*
HW:BW ratio (mg/g) 2.45G0.06 2.37G0.09 5.39G0.23* 4.33G0.15*
,†
HW:LBM ratio (mg/g) 2.81G0.09 2.94G0.15 5.66G0.19* 4.73G0.33*
,†
Lung (g) 1.21G0.05 1.20G0.06 2.09G0.34* 2.05G0.24*
Lung:BW ratio (mg/g) 3.64G0.12 3.30G0.24 7.83G1.39* 6.02G0.73
Kidney (g) 1.32G0.04 1.28G0.04 1.04G0.03* 1.23G0.07
†
Kidney:BW ratio (mg/g) 3.99G0.18 3.56G0.15 3.90G0.19 3.58G0.21
Liver (g) 12.15G0.50 11.72G0.53 9.07G0.47* 12.48G0.78
†
Liver (% of body weight) 3.69G0.19 3.19G0.13 3.35G0.23 3.59G0.29
Lean body mass (g)
Baseline 265.7G3.35 261.0G4.99 243.2G7.12* 248.0G5.08
Percentage of body weight 88.43G1.41 87.75G1.13 87.44G2.17 87.79G1.05
After treatment 298.6G4.91
‡ 300.4G9.67
‡ 251.2G8.80* 298.9G8.82
†,‡
Percentage of body weight 89.58G0.61 83.70G1.80
† 90.95G0.70 86.11G1.89
Fat mass (g)
Baseline 25.52G1.18 24.30G2.94 18.17G1.68 17.94G1.27
Percentage of BW 7.97G0.26 8.79G0.95 6.87G0.59 6.83G0.42
After treatment 26.91G1.13 58.95G7.72
†,‡ 18.46G2.50 44.04G3.61
†,‡
Percentage of BW 8.37G0.26 16.91G1.69
†,‡ 7.06G0.98 12.78G1.41*
,†,‡
Sham, sham-operated rats; Band, aortic-banded rats; aCSF, i.c.v. aCSF treatment; AGRP, i.c.v. AGRP treatment; BW, body weight. *P!0.05 versus respective
sham group;
†P!0.05 versus respective aCSF group;
‡P!0.05 versus baseline.
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and wet lung weights between Band-aCSF and Band-AGRP
animals. Serum concentrations of TNF-a were not signi-
ﬁcantly different between banded rats and sham-operated rats
(banded 0.21G0.08 pg/ml versus sham-operated
0.14G0.09 pg/ml, PZNS). Band-aCSF rats had kidney
and liver weights that were signiﬁcantly decreased compared
to Sham-aCSF rats (Table 2). AGRP treatment signiﬁcantly
increased kidney and liver weights in banded rats (Band-aCSF
versus Band-AGRP; Table 2), and the ﬁnal kidney and liver
weights of Band-AGRP rats were not different compared to
Sham-aCSF rats (Table 2). No signiﬁcant differences in the
hypothalamic mRNA expression of Pomc, Agrp, neuropeptide
Y, Il1b, Il1r, prohormone convertase 1 (Pc1 or Pcsk1 as
listed in the MGI Database), and Pc2 (Pcsk2)w e r e
found between Sham-aCSF, Sham-AGRP, Band-aCSF, and
Band-AGRP rats. The survival rate for both banded and
sham-operated rats that received either saline or AGRP for
2 weeks was 100% over the 2-week injection period.
Discussion
In agreement with results from a previously published study
(Gould et al. 2002), WT mice that received permanent LAD
ligation surgeries developed physiologic abnormalities
consistent with a cachectic state including weight loss,
reduced LBM, reduced fat mass accumulation, and organ
atrophy. In contrast, MC4-MI mice as a group did not
become cachectic as shown by their normal accumulation of
LBM, fat mass, and overall normal gross organ weights as
compared to MC4-Sham mice. These results argue that in
addition to attenuating cachexia in the acute illness, loss of
MC4R signaling is also effective in providing prolonged
protection against the development of cachexia in the setting
of a chronic illness. In comparing the survival of MC4-MI
mice to WT-MI mice after surgery, we observed that a greater
percentage of MC4-MI mice survived compared to WT-MI
mice, though this difference did not achieve statistical
signiﬁcance in this study. However, these results do suggest
that melanocortin blockade may confer a survival advantage
in the setting of heart failure, and that additional experiments
with larger groups of animals may be warranted to further
investigate this possibility.
Although a direct measurement of cardiac function via
Doppler ultrasound was not performed in this study, both
WT-MI and MC4-MI mice achieved HW:BW ratios that
were signiﬁcantly greater than their respective sham controls.
Previous studies have demonstrated that mice with elevated
HW:BW ratios similar to those measured in our study are
consistent with the animals being in heart failure (Nahrendorf
et al. 2003, Shioura et al. 2007, 2008). In addition, the
increased wet lung weights of both WT-MI and MC4-MI
suggest that these animals had developed signiﬁcant pulmon-
ary edema, providing further support that these animals were
in a state of heart failure. One concern at the beginning of the
study is thatloss ofMC4R signaling could potentiallyalter the
sensitivity of the hearts to the effects of the MI procedure.
Ending HWs for sham-operated mice (WT-Sham versus
MC4-Sham) and MI mice (WT-MI versus MC4-MI) were
not different from each other. These results argue against the
loss of MC4R signaling providing a protective effect against
ischemic damage as a result of the MI procedure, or altering
the subsequent development of cardiohypertrophy.
To test the ability of speciﬁc blockade of central MC4R
signaling to attenuate cardiac cachexia, we utilized a
pharmacological approach by administering multiple i.c.v.
injections of AGRP to animals that had developed cardiac
cachexia. For this experiment, we decided to use a rat model
of left ventricular pressure overload hypertrophy, a well-
characterized model of cardiac cachexia (Helies-Toussaint
et al. 2005). At the beginning of the treatment period, banded
rats were hypophagic, and had reduced BWs, LBM, and fat
mass accumulation compared to sham-operated rats. AGRP
treatment in banded rats was effective in attenuating the
cachectic state as evidenced by the signiﬁcant increases in
food intake, LBM, and fat mass accumulation while receiving
treatment. Feed efﬁciency, a measurement of weight gain per
unit offood consumed, was signiﬁcantly increased by banding
and was reversed by AGRP treatment. These results support
the conclusion that the observed increases in weight, LBM,
and fat mass in Band-AGRP rats were not only due to AGRP
increasing food intake, but also due to AGRP decreasing the
increased metabolic rate that results from the banding
procedure. Although our current study was not designed to
measure the effect of AGRP treatment on morbidity in
banded rats, we observed during the treatment period that
Band-AGRP rats were more active and better groomed
compared to Band-aCSF rats. Indirect calorimetry measure-
ments may have provided some information regarding the
relative activity of the groups, but these measurements were
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Figure 4 Effect of AGRP versus aCSF administration on the
accumulation of LBM in sham-operated and aortic-banded rats.
Data are meanGS.E.M.* P!0.05 versus Band-aCSF; **P!0.01
versus Band-aCSF; ***P!0.001 versus Band-aCSF.
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be used for adult rats. Final gross HWs for sham-operated
rats (Sham-aCSF versus Sham-AGRP) and banded rats
(Band-aCSF versus Band-AGRP) were not different from
each other respectively, demonstrating that central AGRP
treatment did not promote cardiohypertrophy in sham rats,
nor prevent cardiohypertrophy from occurring in banded
rats. Collectively, these results reveal that blockade of central
melanocortin signaling with AGRP is both sufﬁcient and
successful in attenuating cardiac cachexia in the aortic-banded
rat model of pressure overload cardiac hypertrophy.
In human patients with CHF, elevated levels of the
proinﬂammatory cytokine TNFa have been measured in
patients that have developed cardiac cachexia (Anker &
Sharma 2002), and have been correlated with worsening
cachexia (Dutka et al. 1993, Anker et al. 2004). In contrast to
these human studies, we did not ﬁnd signiﬁcant increases in
serum TNFa in either our mouse or rat models of cardiac
cachexia. Similar to our results, the absence of a signiﬁcant
rise in serum TNFa in a murine model of MI-induced CHF
has also been reported by another group (Schulze et al. 2003),
raising the intriguing possibility that this may be representa-
tive of a species-speciﬁc difference between humans and
rodents in the peripheral inﬂammatory response to CHF. In
the absence of a robust peripheral TNF-a response, the
question is then raised howelse could inﬂammatory signals be
relayed to the brain to increase central melanocortin
signaling? One alternative hypothesis is that afferent ﬁbers
from autonomic nerves that innervate the heart relay
stimulatory signals to the brain from the chronically inﬂamed,
failing heart. Indeed, the ability of autonomic ﬁbers that
innervate the heart to stimulate the production of proin-
ﬂammatory cytokines in the hypothalamus has already been
demonstrated in a murine model of acute MI (Francis et al.
2004). Combined with recent data that have clearly
established that central paracrine production of cytokines
within the brain (by resident microglia) is both necessary and
sufﬁcient for the production of a cachectic state (Ogimoto
et al. 2006, Wisse et al. 2007), it is possible in rodents that the
development of cachexia in the setting ofCHF is independent
of a signiﬁcant rise in peripheral proinﬂammatory cytokines.
Although we found no signiﬁcant differences in the
hypothalamic expression of either IL1b or IL1R, there
remains many additional proinﬂammatory cytokines capable
of promoting a cachectic state including TNF-a, IL6, and
leukemia inhibitory factor whose expression in the hypo-
thalamus in the setting of CHF remains to be investigated.
In addition to being expressed in the brain, Mc4r mRNA
expression has also been demonstrated in peripheral systems,
including the heart and lung (Mountjoy et al. 2003). This
observation raises the possibility that increased peripheral
MC4R signaling may be contributing to the pathogenesis of
cardiac cachexia, and that blockade of this signaling as would
occur with MC4RKO mice might contribute to the
prevention of cardiac cachexia. Phenotypic analysis of
MC4RKO mice has failed to reveal the development of
any cardiovascular abnormalities, and humans with defective
MC4R genes have not been reported to suffer from increased
cardiovascular problems independent of those associated with
their increased risk of developing the metabolic syndrome.
Ourobservation in this study that central injections of AGRP,
a neuropeptide that is incapable of crossing the blood–brain
barrier, are able to attenuate cardiac cachexia in our rat model
of CHF strongly suggests that central MC4R signaling is the
principle driving force for the cachectic state, and that the
relative contribution of MC4R signaling from the periphery
is likely minor. Although the functional role of MC4R
signaling in the cardiorespiratory system remains to be eluci-
dated, there is evidence that the MC3R plays a protective role
in acute and delayed heart reperfusion injury (Mioni et al.
2003, Getting et al. 2004). Activation of MC3R led to
reduced myocardial cytokine production and myeloperox-
idase activity, and these effects were prevented by the mixed
MC3/4R antagonist SHU9119, but not by the selective
MC4R antagonist HS204 (Getting et al. 2004).
An interesting observation in our study was that the
blockade of central melanocortin signaling resulted in
signiﬁcantly increased adiposity in rats with cardiac cachexia
due to left ventricular pressure overload hypertrophy.
Repeated injections of AGRP have been shown to cause
hyperphagia and obesity in healthy rats and mice (Small et al.
2001). However, this is the ﬁrst study that shows that these
results also occur in rodents that have cardiac cachexia at
baseline. Although increased adiposity is a risk factor for
cardiovascular disease and the subsequent development of
CHF (Kenchaiah et al. 2002), data suggest that once CHF has
developed, overweight and obese patients paradoxically have
better prognosis and lower mortality risks than lean patients
(Curtis et al. 2005). Band-AGRP rats had signiﬁcantly
more fat mass than Sham-aCSF rats (Table 2), but unlike
MC4RKO mice where the increased adiposity has the
adverse outcome of pronounced liver steatosis, we did not
observe liver steatosis in the Band-AGRP rats.
In summary, our data suggest that the central melanocortin
system, a neural integrator of hormone and cytokine
signaling that regulates feeding behavior, linear growth, and
metabolic rate, may play a key role in the pathogenesis of
cardiac cachexia.
The ability of genetic and pharmacologic blockade of
melanocortin signaling to increase both LBM and fat mass in
rodent models of CHF suggests that compounds that
selectively antagonize central melanocortin signaling may
have important pharmacotherapeutic beneﬁts for cachectic
CHF patients.
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